Teduglutide vs MOTS-c
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
TeduglutideAnti-Aging & Longevity
MOTS-c- Summary
- Teduglutide is a GLP-2 (glucagon-like peptide-2) analog with enhanced stability. Unlike GLP-1, GLP-2 specifically acts on the intestinal epithelium to increase intestinal length, villus height, and absorption surface area. FDA-approved as Gattex for short bowel syndrome, it is also being investigated for IBD, leaky gut, and mucosal healing.
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- Half-Life
- ~2 hours; once-daily dosing due to gut-specific residence
- Estimated 1–2 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.05 mg/kg/day
- 5–15 mg
- Frequency
- Once daily
- 3–5 times per week
- Key Benefits
- Increases intestinal villus height and absorption surface area
- Reduces intestinal permeability (leaky gut)
- FDA-approved for short bowel syndrome
- Reduces parenteral nutrition dependence in SBS patients
- Promotes intestinal mucosal healing in IBD
- Increases tight junction proteins ZO-1 and occludin
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- Side Effects
- Injection site reactions
- Abdominal pain and bloating
- Nausea
- Risk of intestinal polyp growth (requires colonoscopy surveillance)
- +1 more
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Stacks With
- —
- —